Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)
China · Delayed Price · Currency is CNY 7.88
-0.34 (-4.14%)
Sep 10, 2026, 1:45 PM CST
SHA:600222 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,545 | 3,638 | 2,823 | 3,429 | 3,544 | 5,056 | |
Market Cap Growth | 20.70% | 28.87% | -17.66% | -3.25% | -29.90% | 84.84% |
Enterprise Value | 5,334 | 4,276 | 3,456 | 3,965 | 3,814 | 5,742 |
Last Close Price | 8.22 | 6.57 | 5.08 | 6.08 | 6.32 | 8.89 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 86.22 | 60.64 | 55.88 | 78.72 | - | 843.33 |
Forward PE | - | 47.05 | 47.05 | 47.05 | 47.05 | 47.05 |
PS Ratio | 2.62 | 2.07 | 1.45 | 1.66 | 1.81 | 3.15 |
PB Ratio | 2.72 | 2.19 | 1.74 | 2.11 | 2.20 | 2.84 |
P/TBV Ratio | 3.55 | 2.87 | 2.28 | 2.77 | 2.87 | 3.83 |
P/FCF Ratio | 57.28 | 139.74 | - | 5673.80 | - | 83.46 |
P/OCF Ratio | 45.99 | 77.15 | - | 78.40 | - | 50.74 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.08 | 2.43 | 1.78 | 1.92 | 1.95 | 3.58 |
EV/EBITDA Ratio | 29.16 | 22.96 | 27.06 | 31.16 | 96.86 | 33.91 |
EV/EBIT Ratio | 42.75 | 31.72 | 45.53 | 52.21 | - | 45.81 |
EV/FCF Ratio | 67.23 | 164.23 | - | 6560.68 | - | 94.77 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.57 | 0.46 | 0.63 | 0.48 | 0.41 | 0.69 |
Debt / EBITDA Ratio | 5.09 | 3.88 | 7.28 | 5.42 | 12.08 | 6.71 |
Debt / FCF Ratio | 11.93 | 29.60 | - | 1290.72 | - | 20.22 |
Net Debt / Equity Ratio | 0.44 | 0.27 | 0.47 | 0.27 | 0.17 | 0.31 |
Net Debt / EBITDA Ratio | 4.14 | 2.40 | 5.99 | 3.38 | 7.10 | 3.30 |
Net Debt / FCF Ratio | 9.22 | 17.17 | -9.96 | 711.63 | -1.46 | 9.22 |
Asset Turnover | 0.48 | 0.49 | 0.55 | 0.58 | 0.53 | 0.45 |
Inventory Turnover | 2.66 | 3.52 | 3.50 | 3.33 | 3.59 | 3.14 |
Quick Ratio | 0.92 | 0.90 | 0.80 | 0.88 | 0.86 | 0.89 |
Current Ratio | 1.26 | 1.14 | 1.06 | 1.21 | 1.18 | 1.18 |
Return on Equity (ROE) | 3.39% | 4.00% | 3.29% | 2.77% | -4.47% | 0.41% |
Return on Assets (ROA) | 2.21% | 2.36% | 1.34% | 1.32% | -0.13% | 2.18% |
Return on Invested Capital (ROIC) | 4.26% | 5.09% | 3.42% | 3.85% | -0.37% | 5.07% |
Return on Capital Employed (ROCE) | 6.60% | 7.60% | 4.50% | 3.90% | -0.40% | 5.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.16% | 1.65% | 1.79% | 1.27% | -2.04% | 0.12% |
FCF Yield | 1.75% | 0.72% | -2.72% | 0.02% | -5.39% | 1.20% |
Dividend Yield | 0.16% | 0.21% | 0.55% | 0.30% | - | 0.11% |
Payout Ratio | 110.46% | 84.61% | 136.70% | 115.18% | - | 1410.34% |
Buyback Yield / Dilution | 0.23% | 0.63% | 1.12% | -0.07% | -0.36% | -2.52% |
Total Shareholder Return | 0.39% | 0.84% | 1.67% | 0.22% | -0.36% | -2.40% |